Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Determine the diagnostic value of 18F-PSMA-11 in patients with iodine refractory thyroid cancer.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Overal Trial | Other | only one arm in this trial |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PET/CT scan F18-PSMA-11 | Diagnostic Test | PET/CT scan with F18-PSMA-11 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Demonstrate uptake of 18F-PSMA-11 in RAI-RTC | Confirmation in PET-scan that lesions in RAI-RTC show uptake of 18F-PSMA-11, above background activity in the bloodpool. | 60 minutes +- 5 minutes after injection 18F-PSMA-11 |
| Measure | Description | Time Frame |
|---|---|---|
| Perform a semi-quantitative analysis of radiotracer uptake in lesions. | 60 minutes +- 5 minutes after injection 18F-PSMA-11 | |
| Perform a lesion detection rate analysis on organ level. | 60 minutes +- 5 minutes after injection 18F-PSMA-11 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University hospital Ghent | Ghent | Belgium |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39264376 | Result | Van den Broeck B, Debacker JM, Bauters W, Creytens D, Ferdinande L, Huvenne W, Lapauw B, Schelfhout V, Van Laeken N, Verroken C. Potential application of [18F]AlF-PSMA-11 PET/CT in radioiodine refractory thyroid carcinoma. EJNMMI Res. 2024 Sep 12;14(1):82. doi: 10.1186/s13550-024-01148-9. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D013964 | Thyroid Neoplasms |
| ID | Term |
|---|---|
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D006258 | Head and Neck Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Compare uptake of 18F-PSMA-11 in these patients to the uptake of 18F-FDG, on a lesion basis. | 60 minutes +- 5 minutes after injection 18F-PSMA-11 |
| Evaluate the sufficiency of uptake of 18F-PSMA-11 to consider therapy with 177Lu-PSMA in a subset of patients | 60 minutes +- 5 minutes after injection 18F-PSMA-11 |
| Compare the histological expression of PSMA on already available tumor samples with the uptake of lesions on PSMA PET. | 60 minutes +- 5 minutes after injection 18F-PSMA-11 |
| Analyse the correlation between the serum level of PSMA and the uptake on PSMA PET | 60 minutes +- 5 minutes after injection 18F-PSMA-11 |
| Compare the histological expression of PSMA on already available tumor samples with the serum level of PSMA. | Within 1 year |
| D004700 |
| Endocrine System Diseases |
| D013959 | Thyroid Diseases |